Articles related to LIPID MANAGEMENT

Synthetic DNA molecules known as polypurine reverse Hoogsteen hairpins reduced PCSK9 expression and lowered LDL cholesterol by approximately 50% in preclinical models, representing an early-stage gene-targeted approach distinct from existing monoclonal antibody and RNA interference strategies.

Lerochol (lerodalcibep-liga), a once-monthly self-administered PCSK9 inhibitor, is now commercially available as adjunctive LDL-C-lowering therapy for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

Prenatal exposure to medications that inhibit sterol biosynthesis was associated with higher rates of autism spectrum disorder diagnosis in a 6.14-million-record retrospective analysis.

ACC/AHA’s 2026 dyslipidemia guideline reintroduces LDL-C and non-HDL-C treatment goals, replaces Pooled Cohort Equations with PREVENT, and recommends one-time lipoprotein(a) measurement in all adults.

Extreme LDL-C in young patients with family history points toward familial hypercholesterolemia, a common genetic disorder that remains undiagnosed in 70% of cases.

Rare lipid disorders can drive extreme cholesterol abnormalities and early disease, making clinical recognition critical when lipid patterns don’t fit typical cardiology presentations.